Active Immuno-Oncology Therapy
OBI-833 is another Globo H-based active immunotherapy. Its safety has been assessed in a Phase I dose escalation and cohort expansion study. OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. In addition, OBI-833 rendered some non-small cell lung cancer patients who were treated with a TKI durable stable disease status. A Phase II study is being prepared.